ADOCIA concludes a financial agreement with Vester Finance

The French biopharmaceutical company ADOCIA has signed an agreement with Vester Finance for a shareholder current account advance. The two-year agreement provides a financing line of up to €6 million. €1.5 million has been disbursed immediately, with an option for repayment in shares or cash. This will allow ADOCIA to extend its cash runway until the beginning of the second quarter of 2027.

The funds will be used to develop the BioChaperone® and AdoXLong™ platforms. Vester Finance, which currently holds 4.2% of the company's capital, will see its stake increase significantly. This transaction is designed to strengthen ADOCIA's financial position while avoiding the requirement for a prospectus to be submitted to the AMF (French Financial Markets Authority).